Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
17.06. | CG Oncology stock price target raised to $56 from $52 at Morgan Stanley | 3 | Investing.com | ||
06.06. | CG Oncology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
22.05. | CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success | 2 | Zacks | ||
13.05. | CG Oncology, Inc. GAAP EPS of $0.45 | 1 | Seeking Alpha | ||
CG ONCOLOGY Aktie jetzt für 0€ handeln | |||||
13.05. | CG Oncology, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
13.05. | CG Oncology, Inc. - 8-K, Current Report | - | SEC Filings | ||
13.05. | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | 467 | GlobeNewswire (Europe) | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
02.05. | JPMorgan sets CG Oncology stock overweight, $41 target | 6 | Investing.com | ||
29.04. | UBS maintains CG Oncology stock Buy rating, $60 target | 3 | Investing.com | ||
29.04. | Why CG Oncology, Inc. (CGON) Surged on Monday | 1 | Insider Monkey | ||
28.04. | CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why | 1 | Benzinga.com | ||
28.04. | CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug | 4 | Investor's Business Daily | ||
28.04. | Cantor Fitzgerald maintains CG Oncology stock with $75 target | 4 | Investing.com | ||
28.04. | CG Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
26.04. | CG Oncology Inc.: CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting | 263 | GlobeNewswire (Europe) | - Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C - - 58.3% of patients showed durable complete responses by K-M at 24 months - - 97.3% of... ► Artikel lesen | |
31.03. | HC Wainwright maintains CG Oncology stock Buy rating, $75 target | 16 | Investing.com | ||
28.03. | CG Oncology announces mixed shelf offering | 3 | Seeking Alpha | ||
28.03. | CG Oncology, Inc. GAAP EPS of -$0.46 | 2 | Seeking Alpha | ||
28.03. | CG Oncology, Inc. - 10-K, Annual Report | - | SEC Filings | ||
28.03. | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | 328 | GlobeNewswire (Europe) | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | EQS-News: Evotec SE: Evotecs Partnerschaft mit dem NURTuRE-AKI Konsortium ermöglicht innovative therapeutische Ansätze basierend auf molekularem Verständnis von akutem Nierenversagen | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotecs Partnerschaft mit dem NURTuRE-AKI Konsortium ermöglicht innovative therapeutische Ansätze basierend auf molekularem Verständnis... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | Biotech Report: Biontech rutschen ab; Sektor an der Wall Street leichter | (shareribs.com) Frankfurt / New York 23.06.2025 - Biotech-Aktien zeigen sich im deutschen Handel überwiegend leichter. Unter anderem sacken Biontech kräftig ab. Auch an der Wall Street bewegt sich der... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target | ||
ONCO-INNOVATIONS | 1,380 | +0,73 % | EQS-Media: Onco-Innovations Ltd.: Erhebliche Aufwärtsperspektive für frühe Investoren? Neue Studie unterstützt die Anwendbarkeit der Ergebnisse klinischer Lungenkrebsstudien | EQS-Media / 21.06.2025 / 15:37 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass die Mitbegründer seiner hundertprozentigen... ► Artikel lesen |